Genmab
GMAB
227 hedge funds and large institutions have $1.44B invested in Genmab in 2024 Q1 according to their latest regulatory filings, with 42 funds opening new positions, 88 increasing their positions, 73 reducing their positions, and 39 closing their positions.
21% more repeat investments, than reductions
Existing positions increased: 88 | Existing positions reduced: 73
8% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 39
1% more funds holding
Funds holding: 225 → 227 (+2)
0.32% more ownership
Funds ownership: 72.22% → 72.54% (+0.32%)
5% less capital invested
Capital invested by funds: $1.51B → $1.44B (-$75.4M)
28% less call options, than puts
Call options by funds: $977K | Put options by funds: $1.36M
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$21.6M |
| 2 |
BlackRock
New York
|
+$19.3M |
| 3 |
Capital International Investors
Los Angeles,
California
|
+$9.26M |
| 4 |
Voloridge Investment Management
Jupiter,
Florida
|
+$7.97M |
| 5 |
Two Sigma Investments
New York
|
+$7.37M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$35.4M |
| 2 |
Stifel Financial
St. Louis,
Missouri
|
-$12.9M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
-$10.6M |
| 4 |
HJGA
Hardman Johnston Global Advisors
Stamford,
Connecticut
|
-$6.47M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$6.03M |
GMAB Hedge Fund Activity: Q1 2024 in Review
227 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Genmab (GMAB) for Q1 2024, worth a combined $1.44B — down 5% from $1.51B a quarter earlier.
Buyers outnumbered sellers: 42 funds opened new GMAB positions and 39 closed out — a net gain of 3 holders — while 88 added to existing stakes and 73 trimmed.
The largest buyer was Marshall Wace, adding an estimated $21.6M. The largest seller was Morgan Stanley, cutting an estimated $35.4M.
- 227 institutional investors held Genmab (GMAB) as of Q1 2024, up from 225 in Q4 2023.
- Funds reported $1.44B of Genmab stock for Q1 2024, down 5% quarter-over-quarter.
- 42 funds opened new Genmab positions in Q1 2024 and 39 closed out, a net change of +3 holders.
- The largest Genmab buyer in Q1 2024 was Marshall Wace, an estimated $21.6M added.
- The largest Genmab seller in Q1 2024 was Morgan Stanley, an estimated $35.4M sold.
Based on aggregated 13F filings for Q1 2024.